Introduction and Epidemiology
Disease Overview
- Non-Hodgkin Lymphoma (NHL) is a heterogeneous group of high-grade lymphoproliferative neoplasms arising from malignant B or T lymphoid progenitor cells.
- Lymphomas represent the third most common pediatric malignancy, accounting for 10-15% of all childhood cancers.
- NHL constitutes approximately 60% of all childhood lymphomas, while Hodgkin Lymphoma accounts for the remaining 40%.
- Pediatric NHL accounts for 6-8% of total childhood cancers in patients under 20 years of age.
Epidemiological Characteristics
- The annual incidence of pediatric NHL is approximately 7-10 cases per million children or 1 per 100,000.
- In India, the reported incidence of NHL among pediatric malignancies ranges from 12% to 25%.
- There is a marked male preponderance, with a male-to-female ratio of 3:1 in children under 15 years.
- NHL is uncommon in children younger than 3 years of age.
- The incidence increases steadily with age, peaking during the second decade of life.
- Unlike adult NHL, which is predominantly indolent and nodal, pediatric NHL is overwhelmingly high-grade (>95%), rapidly proliferating, and extranodal (>70% presenting with advanced Stage III or IV disease).
Histopathological Classification and Biology
Comparative Subtype Characteristics
| Subtype | Immunophenotype | Histopathology & Cytogenetics | Common Clinical Sites |
|---|---|---|---|
| Burkitt Lymphoma (BL) | Mature B-cell (sIg+, PAX5, CD10, CD19, CD20, CD22, CD38, CD79a, kappa/lambda+) | Starry-sky pattern; Ki-67 >99%; t(8;14)(q24;q32), t(2;8), t(8;22) MYC translocations | Abdomen (ileocecal), head/neck (Waldeyer ring, jaw), testes, bone marrow |
| Lymphoblastic Lymphoma (LL) | Immature T-cell (70%) or precursor B-cell (30%); TdT+, CD34+ | Convoluted lymphoblasts; T-cell receptor rearrangements t(1;14), t(11;14), del 9p | Anterior mediastinum, bone marrow, skin, bone, central nervous system |
| Diffuse Large B-Cell Lymphoma (DLBCL) | Mature B-cell (CD19, CD20, CD22, CD38, CD79a) | Diffuse growth of large cells; 2p16 amplification, 1p36 deletion, t(8;14) in 30% | Nodal, abdominal, mediastinal (PMBL variant) |
| Anaplastic Large Cell Lymphoma (ALCL) | Mature T-cell / null cell; CD30+, ALK (CD246)+, EMA+ | Pleomorphic cells with horseshoe nuclei; t(2;5)(p23;q35) NPM-ALK fusion | Lymph nodes, skin, bone, visceral organs, soft tissue |
Detailed Subtype Profiles
Burkitt Lymphoma
- Burkitt Lymphoma represents 19-38% of all pediatric NHL cases.
- Histopathology shows a diffuse monomorphic infiltrate of medium-sized lymphoid cells with round nuclei and basophilic vacuolated cytoplasm.
- Benign macrophages phagocytosing apoptotic debris create the classic starry-sky appearance.
- Driven by MYC oncogene dysregulation resulting from chromosomal translocations involving immunoglobulin locus promoters.
- Secondary mutations frequently involve TCF3, ID3, ARID1A, and SMARCA4 genes.
Lymphoblastic Lymphoma
- Lymphoblastic Lymphoma accounts for approximately 20-29% of pediatric NHL cases.
- Biologically and morphologically identical to acute lymphoblastic leukemia (ALL).
- T-cell LL accounts for 70-80% of LL cases and typically presents as a rapidly expanding anterior mediastinal mass.
- B-cell precursor LL accounts for 20-30% of cases and presents as localized lymphadenopathy, cutaneous nodules, or isolated bone lesions.
Diffuse Large B-Cell Lymphoma
- Accounts for 10-20% of pediatric NHL cases.
- The majority belong to the favorable germinal center B-cell-like subtype.
- Primary Mediastinal Large B-Cell Lymphoma (PMBL) is a distinct subtype sharing molecular features with Hodgkin Lymphoma and carrying a less favorable prognosis with standard regimens.
Anaplastic Large Cell Lymphoma
- Represents approximately 10-17% of pediatric NHL cases.
- Characterized by large pleomorphic lymphoid cells with abundant cytoplasm and eccentric horseshoe-shaped or kidney-shaped nuclei.
- Over 90% of pediatric ALCL cases express anaplastic lymphoma kinase (ALK) fusion protein due to the t(2;5)(p23;q35) translocation.
Rare Pediatric Lymphomas
- Includes Pediatric-type Follicular Lymphoma (PFL), which carries 1p36 deletion and MAP2K1 mutations without BCL2 rearrangements.
- Other rare entities include Pediatric Marginal Zone Lymphoma and MALT Lymphoma.
Distinguishing Features: Non-Hodgkin vs Hodgkin Lymphoma
| Clinical / Biological Feature | Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
|---|---|---|
| Anatomical Extent | Localized to nodal groups | Disseminated, extranodal presentation common |
| Pattern of Spread | Contiguous orderly spread to adjacent nodes | Discontinuous non-contiguous spread |
| Extranodal Disease | Rare | Common (>70% of cases at diagnosis) |
| Abdominal Involvement | Uncommon | Common (especially Burkitt subtype) |
| Bone Marrow & CNS Involvement | Rare (<5-10%) | Common (up to 20-30% at diagnosis) |
| Systemic B Symptoms | Present in 20-30%; prognostic | Present in 8-10% (higher in ALCL); non-prognostic |
| Growth Fraction | Low to variable growth fraction | Extremely high growth fraction |
| Treatment Basis | Risk-stratified by stage and B symptoms | Subtype-specific intensive multiagent chemotherapy |
| Overall Survival Rates | 85-90% | 70-90% |
Clinical Presentation and Emergencies
Organ-Specific Presentations
- Abdominal Presentations: Most frequent in Burkitt Lymphoma. Patients present with abdominal pain, ascites, a rapidly expanding right lower quadrant mass, or acute ileocecal intussusception.
- Intrathoracic Presentations: Most frequent in T-cell Lymphoblastic Lymphoma. Patients present with cough, dyspnea, orthopnea, stridor, and pleural or pericardial effusions.
- Head and Neck Presentations: Cervical lymphadenopathy, tonsillar hypertrophy (Waldeyer ring involvement), or jaw swelling.
Oncologic Emergencies
- Superior Mediastinal Syndrome / SVC Obstruction: Caused by compression of the trachea and superior vena cava by an anterior mediastinal mass. Requires urgent administration of intravenous dexamethasone.
- Acute Tumor Lysis Syndrome (TLS): High risk in Burkitt and Lymphoblastic Lymphoma due to rapid tumor growth. Causes hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute oliguric renal failure.
- Spinal Cord Compression: Caused by paraspinal or epidural tumor extension leading to paraplegia, sensory deficits, or bowel/bladder dysfunction. Requires emergency high-dose corticosteroids and prompt cytoreductive therapy.
Staging and Risk Stratification
Murphy / St. Jude Staging System
- Stage I: A single extranodal tumor or single anatomical nodal area, excluding the mediastinum or abdomen.
- Stage II: A single extranodal tumor with regional node involvement; OR two or more nodal areas on the same side of the diaphragm; OR a completely resected primary gastrointestinal tract tumor ± mesenteric nodes.
- Stage III: Two single extranodal tumors on opposite sides of the diaphragm; OR two or more nodal areas above and below the diaphragm; OR any primary intrathoracic tumor; OR extensive intra-abdominal disease; OR any paraspinal/epidural tumor.
- Stage IV: Any of the above stages with initial central nervous system (CNS) and/or bone marrow (BM) involvement (defined as ≤25% blasts in marrow).
International Pediatric Non-Hodgkin Lymphoma Staging System
- International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) incorporates modern flow cytometry, molecular assays, and PET-CT imaging.
- Stage IV BM is defined morphologically by ≥5% blasts in bone marrow aspiration.
- Sub-classifies marrow involvement as BMm (morphology positive), BMi (immunophenotypic positive), or BMmol (molecular positive).
Diagnostic Evaluation
Histopathological and Molecular Workup
- Excisional or core lymph node biopsy is the gold standard for diagnosis.
- Diagnostic panel must include histopathology, immunohistochemistry, immunophenotyping by flow cytometry, cytogenetics/FISH, and molecular diagnostics.
- In patients with severe respiratory compromise from a mediastinal mass, diagnosis can be established using percutaneous needle aspiration, fluid cytology (pleural/peritoneal), or bone marrow aspiration.
Staging Investigations
- Laboratory Panel: Complete blood count, peripheral smear, liver function tests, renal function tests, serum electrolytes, uric acid, and lactate dehydrogenase (LDH).
- Bone Marrow Examination: Bilateral iliac crest bone marrow aspirates and trephine core biopsies.
- Central Nervous System Evaluation: Lumbar puncture with CSF cytomorphology and flow cytometry.
- Diagnostic Imaging: Contrast-enhanced CT or MRI of neck, chest, abdomen, and pelvis. Positron emission tomography (FDG-PET/CT) for baseline staging and response assessment. Echocardiogram prior to anthracycline therapy.
Management Principles
Supportive Care and Tumor Lysis Syndrome
- Vigorous intravenous hydration at 2-3 L/m²/day without added potassium.
- Rasburicase (recombinant urate oxidase) administered at 0.2 mg/kg/day IV for rapid clearance of uric acid.
- Rasburicase is strictly contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of severe hemolysis.
- Allopurinol (10 mg/kg/day orally in 3 divided doses) is utilized in low-risk cases or when rasburicase is contraindicated.
Subtype-Specific Chemotherapy Protocols
Mature B-Cell Lymphomas
- Burkitt Lymphoma and DLBCL are treated with short-duration (3-6 months), pulse-intensive multiagent chemoimmunotherapy.
- Low-stage disease: 2-4 cycles of COPAD (cyclophosphamide, vincristine, prednisone, doxorubicin) or CHOP.
- Advanced-stage disease: FAB-LMB 96 protocol (fractionated cyclophosphamide, high-dose methotrexate, vincristine, doxorubicin, cytarabine, etoposide) combined with anti-CD20 monoclonal antibody (Rituximab).
Lymphoblastic Lymphoma
- Treated on long-duration (2 years) leukemia-like protocols with continuous cytostatic exposure.
- Regimens include BFM-95 or COG A5971, comprising induction, consolidation, CNS prophylaxis, and long-term maintenance phases.
Anaplastic Large Cell Lymphoma
- Regimens include CHOP, APO (doxorubicin, prednisone, vincristine), BFM-NHL90, or ALCL 99.
- Targetable agents include Crizotinib (oral ALK tyrosine kinase inhibitor) and Brentuximab Vedotin (anti-CD30 antibody-drug conjugate).
Role of Immunotherapy and Targeted Agents
- Rituximab (anti-CD20 antibody) significantly improves event-free survival in mature B-cell NHL.
- Crizotinib targets NPM-ALK fusion tyrosine kinase in ALCL.
- Brentuximab Vedotin delivers cytotoxic payload to CD30-expressing ALCL cells.
- Dose-adjusted EPOCH-R is utilized for Primary Mediastinal Large B-Cell Lymphoma.
Role of Surgery and Radiotherapy
- Surgery: Role is limited to diagnostic biopsy and complete resection of primary localized gastrointestinal tumors (ileocecal).
- Radiotherapy: Reserved for acute oncologic emergencies (tracheal compression, spinal cord compression) or specific CNS disease presentations.
Prognosis, Relapse, and Late Effects
Survival Outcomes
- Event-free survival (EFS) exceeds 90-95% for localized low-stage NHL.
- EFS ranges from 80% to 90% for advanced-stage (Stage III/IV) disease with modern chemoimmunotherapy.
Relapse Management
- Relapsed NHL carries a poor prognosis, particularly in Burkitt and Lymphoblastic Lymphoma.
- Reinduction chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is utilized.
- Novel targeted agents under investigation include Obinutuzumab, Ibrutinib, and Idelalisib.
Late Effects of Therapy
- Anthracycline-induced cardiotoxicity.
- Secondary leukemias (AML/MDS) from alkylating agents and topoisomerase II inhibitors.
- Gonadal toxicity resulting in infertility.
- Neurocognitive deficits secondary to intrathecal chemotherapy or cranial radiation.
- Growth retardation and endocrine dysfunction.